New screening tool aims to catch diabetic nerve damage early

NCT ID NCT07163000

Ongoing Diagnosis Sponsor: Weill Cornell Medical College in Qatar Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a short questionnaire called ACT to see if it can accurately detect nerve damage in the feet and legs of people with diabetes. Researchers will compare it to standard screening tools and an eye test that looks at tiny nerve fibers. The goal is to find a simple, non-invasive way to diagnose peripheral neuropathy earlier.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ACT questionnaire
What this could lead to: If successful, this could provide a simple, low-cost way to catch diabetic nerve damage earlier, helping prevent complications.
What could go wrong: This is a small, early-stage validation study, not a treatment trial. The questionnaire may not prove accurate enough for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES (DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus neuropathy, painful peripheral nervous system disorder peripheral neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES (DM) PAINFUL NEUROPATHY PERIPHERAL NEUROPATHY

Contacts and locations

Locations

Weill Cornell Medicine-Qatar

Doha, 24144, Qatar

More trials for these conditions

Other studies related to the condition(s) this trial covers.